• AMPLIRUN® ZIKA VIRUS
    RNA CONTROL

    Guarantee the quality of
    your molecular assays


  • New ZIKV-DENV-CHIKV IFA
    Easy-to-read results for the differential
    serological diagnosis by immunofluorescence


  • VirClia®
    Chemiluminescence in Monotest.
    The perfect combination for infectious serology.


  • Respiratory virus testing
    The complete solution for respiratory virus testing;
    screening and identification


Featured product

ZIKV-DENV-CHIKV IFA

ZIKV-DENV-CHIKV IFA

MEDLAB Middle East

Vircell will once again be attending the greatest exhibition of the IVD industry in Middle East. We would be pleased to welcome you at our stand!

Dubai, 6-9 February 2017, Stand #Z2.J31

More information

Development and production of diagnostic reagents for human infectious diseases

Vircell is a biotechnology company specialized in the development and production of ready to use reagents for human infectious diseases. We are present in laboratories of more than 80 countries worldwide on five continents. Vircell offers more than 400 references for the detection of bacteria, viruses, parasites and fungi by means of different techniques: ELISA, chemiluminescence, direct and indirect immunofluorescence, immunocapture agglutination, cell culture and Molecular Biology (oligochromatography and PCR controls).

Distributors

Vircell is present in laboratories of more than 80 countries worldwide. International Sales constitute one of the major sources of income for the company thanks to the constant work of our commercial team, who has a deep knowledge of the international market. If you need further information on the distribution of our products in your country, do not hesitate to contact us.

More information
23 November 2016 MEDICA 2016 Thank you to everyone that stopped by our booth at MEDICA last week. We had ...
06 February 2017 MEDLAB Middle East 2017 Expanding at a colossal rate, in 2017 MEDLAB Middle East will launch as a standalone ...

Newsletter

Sign up for our newsletter and you will receive our latest news in your e-mail